Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
A mitochondria-encoded peptide that acts on nuclear metabolic programs. It is not a mitochondrial membrane poison and not carnitine.
Forums sometimes file every mitochondrial peptide under SS-31. MOTS-c does not bind cardiolipin the way elamipretide does.
A peptide made from a mitochondrial gene can leave the organelle and change AMPK-related metabolism in preclinical models. Glucose handling and insulin sensitivity are the markers on file.
It does not shuttle fatty acids the way carnitine does, and it does not bind cardiolipin the way elamipretide does.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Exercise and insulin-sensitivity anecdotes · unverified
Forums file MOTS-c under mitochondrial energy and pair it with SS-31 or carnitine. The mechanisms on file are different. The posts treat "mitochondria" as one chemical.
Theme summarized from public discussion. Not a quoted post, not a trial, and not a dose.